TNG: TG4050 achieved 100% 2-year DFS in HNSCC Phase 1; Phase 2 efficacy data due by Q1 2028

Individualized neoantigen vaccine programs TG4050 and TG4070 are advancing in early-stage HNSCC and NSCLC, with TG4050 showing 100% 2-year DFS in Phase 1 and Phase 2 efficacy data expected by Q1 2028. Scalable cell line manufacturing and AI-driven neoantigen selection support expansion, while the company maintains strong ESG commitments and is funded through early 2028.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.